A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

CONCLUSIONS: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy resistant and PD-L1 negative / low tumors.PMID:33820783 | DOI:10.1158/1078-0432.CCR-20-4792

Source: Clinical Cancer Research - April 6, 2021 Category: Cancer & Oncology Authors: Michael Shafique Terrence Lee Fisher Elizabeth E Evans John E Leonard Desa Rae Electa Pastore Crystal L Mallow Ernest S Smith Vikas Mishra Andreas Schr öder Kevin Chin J Thaddeus Beck Megan Ann Baumgart Ramaswamy Govindan Nashat Y Gabrail Alexander I Spi Source Type: research